SU5408

Cat. No.:	HY-103002
CAS No.:	15966-93-5
Molecular Formula:	$C_{18}H_{18}N_2O_3$
Molecular Weight:	310.35
Target:	VEGFR
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 6 mg/mL (19.33 mM; Need ultrasonic and warming)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	3.2222 mL	16.1108 mL	32.2217 mL
	5 mM	0.6444 mL	3.2222 mL	6.4443 mL
	10 mM	0.3222 mL	1.6111 mL	3.2222 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 0.77 mg/mL (2.48 mM); Suspended solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 0.77 mg/mL (2.48 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

SU5408 (VEGFR2 Kinase Inhibitor I) is a potent and cell-permeable inhibitor of VEGFR2 kinase with an IC_{50} of 70 nM.

IC_{50} & Target

VEGFR2
70 nM (IC_{50})

In Vitro

3-Substituted indolin-2-ones have been designed and synthesized as a novel class of tyrosine kinase inhibitors which exhibit selectivity toward different receptor tyrosine kinases (RTKs). These compounds have been evaluated for their relative inhibitory properties against a panel of RTKs in intact cells. SU5408 (VEGFR2 Kinase Inhibitor I) is found to be the most potent and selective VEGFR2 inhibitor among the compounds. SU5408 (VEGFR2 Kinase Inhibitor I) shows little or no effect against receptors for platelet-derived growth factor, epidermal growth factor, or insulin-like growth factor (IC_{50}>100 μM)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Sci Adv. 2021 Feb 10;7(7):eabd8217.
- Angiogenesis. 2020 Aug;23(3):357-369.
- Stem Cells Int. 24 Sept 2022.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Sun L, et al. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity towardparticular receptor tyrosine kinases. J Med Chem. 1998 Jul 2;41(14):2588-603.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA